BMS Reports Five-Year Data of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-III CheckMate -214 for the Treatment of Advanced or Metastatic Renal Cell Carcinoma
Shots:
- The P-III CheckMate -214 trial evaluates Opdivo (3mg/kg) + Yervoy (1mg/kg- q3w for 4 doses) vs sunitinib in 1096 patients with previously untreated advanced/mRCC
- Results: @median follow-up of 67.7mos.- combination showed superior OS in intermediate- poor risk patients & randomized or ITT population; m-OS (47.0 vs 26.6mos.) & (55.7 vs 38.4mos.); ORR (42% vs 27%) & (39% vs 32%); DoR (not reached in all population vs 19.7 & 24.8mos.); CR rate (11% vs 2%) & (12% vs 3%); OS rates @ 5yrs. (43% and 31%) & (48% and 37%) respectively
- Patients were alive (81% vs 72%)- PFS (89% vs 57%)- patients responded (89% vs 63%) @5yrs.- safety profile was manageable & no new safety signals were observed
Ref: BMS | Image: BMS
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com